IBB:NSD-iShares Biotechnology ETF (USD)

ETF | Health |

Last Closing

USD 142.42

Change

-0.32 (-0.22)%

Market Cap

USD 7.39B

Volume

0.69M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-29 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF

-0.47 (-0.51%)

USD 0.69B
BBH VanEck Biotech ETF

+0.02 (+0.01%)

USD 0.45B
PSCH Invesco S&P SmallCap Health Ca..

+0.11 (+0.25%)

USD 0.19B
PTH Invesco DWA Healthcare Momentu..

+0.42 (+0.92%)

USD 0.15B
GNOM Global X Genomics & Biotechnol..

-0.06 (-0.52%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

-0.05 (-0.18%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

-0.26 (-1.70%)

USD 0.01B

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

+0.06 (+0%)

CAD 0.22B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -65.05% 38% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.05% 38% F 10% F
Trailing 12 Months  
Capital Gain -58.24% 25% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.24% 25% F 12% F
Trailing 5 Years  
Capital Gain -55.77% 25% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.77% 25% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 1.99% 38% F 45% F
Dividend Return 2.22% 38% F 42% F
Total Return 0.23% 50% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 20.95% 63% D 75% C
Risk Adjusted Return 10.61% 50% F 44% F
Market Capitalization 7.39B 100% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.